The current stock price of ASPI is 6.54 USD. In the past month the price decreased by -14.62%. In the past year, price increased by 42.17%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SHW | SHERWIN-WILLIAMS CO/THE | 29.45 | 82.57B | ||
| ECL | ECOLAB INC | 35.72 | 73.55B | ||
| PPG | PPG INDUSTRIES INC | 13.15 | 22.67B | ||
| IFF | INTL FLAVORS & FRAGRANCES | 15.37 | 17.20B | ||
| DD | DUPONT DE NEMOURS INC | 9.27 | 16.97B | ||
| ALB | ALBEMARLE CORP | N/A | 14.73B | ||
| RPM | RPM INTERNATIONAL INC | 19.72 | 13.50B | ||
| NEU | NEWMARKET CORP | 16.19 | 7.20B | ||
| EMN | EASTMAN CHEMICAL CO | 9.44 | 7.02B | ||
| ESI | ELEMENT SOLUTIONS INC | 17.95 | 6.39B | ||
| AXTA | AXALTA COATING SYSTEMS LTD | 11.63 | 6.20B | ||
| BCPC | BALCHEM CORP | 30.28 | 4.87B |
ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. The company is headquartered in Washington, Washington Dc. The company went IPO on 2022-11-10. The firm is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The firm employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
ASP ISOTOPES INC
601 Pennsylvania Avenue Nw, South Building, Suite 900
WASHINGTON WASHINGTON DC US
Employees: 136
Phone: 12027562245
ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. The company is headquartered in Washington, Washington Dc. The company went IPO on 2022-11-10. The firm is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The firm employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
The current stock price of ASPI is 6.54 USD. The price decreased by -1.95% in the last trading session.
ASPI does not pay a dividend.
ASPI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ASP ISOTOPES INC (ASPI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
The outstanding short interest for ASP ISOTOPES INC (ASPI) is 20.97% of its float.
ChartMill assigns a technical rating of 1 / 10 to ASPI. When comparing the yearly performance of all stocks, ASPI is one of the better performing stocks in the market, outperforming 75.18% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ASPI. The financial health of ASPI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ASPI reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -134.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.55% | ||
| ROE | -396.17% | ||
| Debt/Equity | 3.98 |
8 analysts have analysed ASPI and the average price target is 13.26 USD. This implies a price increase of 102.75% is expected in the next year compared to the current price of 6.54.
For the next year, analysts expect an EPS growth of -122.81% and a revenue growth 97.58% for ASPI